cancer and semaglutide Clinical Impact of Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential Mitigation of Cardiotoxicity Can GLP-1 Drugs Reduce Cancer

Dual- and triple action approaches which simultaneously target multiple pathways, for example, GLP1R/GIP (tirzepatide), GLP1R/GIP/glucagon (retatrutide) or amylin/GLP1R (CagriSemra) appear more potent and may push weight reduction to the mid-20% range and possibly beyond, while oral options seek to deliver levels of efficacy seen with injectables

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER Severe obesity can also present physical barriers during intimacy, as weight loss improves mobility and comfort

Most people who go on a diet will not lose weight for the long-term, often experiencing a rebound afterward

Larzelere MM, Wiseman P

doi: 10.1038/s41467-024-52528-7 98 WangFJinYWangMLuoH-YFangW-JWangY-Net al